Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer adds doxorubicin hydrochloride injection to portfolio

Pfizer adds doxorubicin hydrochloride injection to portfolio

16th June 2011

Pfizer has announced the addition of injection-based doxorubicin hydrochloride to its portfolio of off-patent oncology products in its injectables division.

The treatment has been shown to help stimulate regression among a wide variety of cancer types, including acute lymphoblastic leukaemia, neuroblastoma, ovarian carcinoma, malignant lymphoma and Hodgkin's disease.

It is also indicated as a component of adjuvant therapy for women with evidence of axillary lymph node involvement following breast cancer resection.

James Hageman, vice-president of Pfizer Injectables, said this will offer a new treatment option for clinicians struggling with a limited supply of oncology treatments.

"We seek to provide our customers with quality established products … so that patients do not have to be turned away as a result of drug shortages," he explained.

Earlier this month, the company applied for European regulatory approval of axitinib, a new developmental therapy for advanced renal cell carcinoma patients that have failed to respond to prior treatment.ADNFCR-8000103-ID-800581029-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.